Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Inhaled Biologics: From Preclinical to Product Approval

Author(s): Kristin Fathe, Silvia Ferrati, Daniel Moraga-Espinoza, Ashkan Yazdi and Hugh D.C. Smyth

Volume 22, Issue 17, 2016

Page: [2501 - 2521] Pages: 21

DOI: 10.2174/1381612822666160210142910

Price: $65

Abstract

Background: Delivery of pharmacologically active compounds to the lung for systemic effects is well known and recently has entered a new era with several products achieving regulatory approval. This review focuses on the barriers to pulmonary delivery of biologics. Methods: Lessons learned from the development of recently approved products will be reviewed to shed light on the current challenges that are faced when developing biological products for inhaled delivery. Results: The text and tables presented herein consolidate the current data and ongoing research regarding biological, inhaled products. Conclusion: With this basis, we also review the future prospects for pulmonary delivery of biologics for systemic delivery and how the biological and physical barriers may be overcome.

Keywords: Systemic pulmonary delivery, biologics, inhalation devices.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy